Search

Wide Consensus Reached at Irish Presidency Conference on ‘Innovation and Patient Access to Personalised Medicine'

DUBLIN, March 25: Wide consensus emerged at the Irish Presidency Conference on ‘Innovation and Patient Access to Personalised Medicine’ on the need for radical change if Europe's approach to healthcare is to benefit from the potential of personalised medicine.

Read more

EHA-SLCH Hematology Tutorial on Hematological Disorders

Date: March 18-19, 2022

Format: Hybrid

EHA and the Sri Lanka College of Haematologists (SLCH) are happy to have successfully organized the EHA-SLCH Hematology Tutorial on Hematological Disorders on March 18 and 19, 2022.

Read more

Highlights of Past EHA (HOPE) EMEA 2020

Highlights of Past EHA (HOPE) EMEA 2020
October 9-10, 2020
Meeting Chairs:

Prof J Gribben (European Hematology Association)
Prof GH Özsan

In the second weekend of October, EHA and the Turkish Society of Hematology (TSH) kicked-off the very first virtual HOPE meeting.…

Read more

EHA-ASH Translational Research Training in Hematology

How to apply for TRTH 2026
The application process for TRTH 2026 is being managed by the American Society of Hematology (ASH).

Read more

EHA-KCS Hematology Tutorial

EHA is joining the Kazakhstan Cancer Society (KCS) to organize the EHA-KCS Hematology Tutorial on Recent Advances in Lymphoid and Myeloid Malignancies.

Read more

Message from the EHA Board

After more than a decade of tireless work to further EHA’s mission our Executive Director, Carin Smand, has unfortunately announced that she will be leaving our organization.

Read more

European Hematology Association publishes new journal with Wolters Kluwer

The European Hematology Association, the largest Europe-based association of hematologists, launched its new journal HemaSphere with publisher Wolters Kluwer at the 22nd Annual Congress of EHA in Madrid.

Read more

Immunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic leukaemia patients

Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.

Read more